Navigation Links
PAREXEL Ranks as a "Best 5 Outsourcing Company for the Pharmaceutical Industry" by IAOP®
Date:8/24/2011

ts.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $18 million over the fourth quarter of Fiscal Year 2011 as well as the first and second quarters of Fiscal Year 2012; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug,  medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.   Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 as filed with the SEC on May 10, 2011, which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-loo
'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PAREXEL Closes the Acquisition of ClinPhone
2. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
3. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
4. PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors
5. PAREXEL International to Present at William Blair Small-Cap Growth Stock Conference
6. PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average
7. PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
8. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
9. PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference
10. PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress
11. PAREXEL Expands Pioneering Asian Ethnobridging Expertise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Dallas, Texas (PRWEB) August 23, 2014 ... on the current state of the Papain industry ... basic overview of the industry, including definitions, applications ... Chinese domestic market analysis are provided with a ... of the market. A comparison between the international ...
(Date:8/22/2014)... Today the Academy of Model Aeronautics (AMA) filed a ... for the D.C. Circuit challenging the FAA’s Interpretation of the ... on June 25, 2014. , The AMA believes that ... intent of the FAA Modernization and Reform Act of 2012, ... new rules or regulations regarding model aircraft that are operated ...
(Date:8/22/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... 30, 2014.  Biorem,s complete 2014 second quarter financial statements and MD&A have ... June 30, , Six-months ended June 30, ( ... 2013 , 2014 , 2013 Revenue , ... 9,195 Gross profit , 56 , 1,485 ...
(Date:8/22/2014)... of Surrey have discovered how the receptors responsible for ... , The new study, published today in The ... in turn regulates the cycle of all cells in ... the local biological clock and its control are weakened ... in bladder physiology and ageing. , While ...
Breaking Biology Technology:Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 3AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2
... Sept. 6, 2011 The Immune Deficiency Foundation (IDF) ... continuing education (CE) course for  nurses. The goal of ... nurses by providing an educational update on primary immunodeficiency ... is the national patient organization dedicated to improving the ...
... 6, 2011 Auxilium Pharmaceuticals, Inc. (NASDAQ: ... safety update following 17 months of post-approval use in ... Dupuytren,s contracture patients with a palpable cord.  After approximately ... U.S., there was no clinically meaningful change in the ...
... Genprex, Inc., formerly known as Convergen LifeSciences, Inc., announced today ... will be branded as Oncoprex™ .   ... oncology sector in recognition of our advancing development programs.  We ... to unlock the unrealized potential of a growing list of ...
Cached Biology Technology:Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy 2Immune Deficiency Foundation Launches Free Accredited Course for Nurses About Primary Immunodeficiency and Immunoglobulin Therapy 3Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 2Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 3Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update 4Genprex Announces New Branding 2
(Date:8/22/2014)... , August 22, 2014 ... ) has announced the addition of ... 2014-2018"  report to their offering.  ... ,Biometrics is a technology that helps ... on their physical or behavioral features. ...
(Date:8/22/2014)... RIVERSIDE, Calif. Thomson Reuters , a leading ... five researchers at the University of California, Riverside in ... brightest minds of our times." , To generate the ... (2002-2012) to identify researchers whose published work has had ... included among some 3,200 individuals who published the greatest ...
(Date:8/22/2014)... the 29th Annual International Papillomavirus Conference shows that ... combats three types of human papillomavirus, including the ... cancer. , When tested in several cultured human ... HPV-18 and HPV-11 cells, according to Louise T. ... the findings at the Seattle conference. The National ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
... Inc. (Nasdaq: AWRE ), a leading supplier of ... to discuss the company,s operating results for the fourth quarter ... 5:00 p.m. Eastern Time. CEO Michael Tzannes and CFO Rick ... webcast by Thomson and can be accessed on the Investor ...
... the potentially fatal hepatitis C virus has banked its ... inability to infect animals other than humans and chimpanzees ... animal model for the disease. But now, in a ... online issue of Nature , Rockefeller University scientists ...
... . , Lack of sleep is a ... the day poses a very real and dangerous problem. ... at McGill University demonstrates interestingly, that sleep-wake states are ... melanin-concentrating hormone (MCH) neurons and orexin (Orx) neurons, which ...
Cached Biology News:Aware Announces Q4 and FY2008 Earnings Conference Call 2Discovery could lead to a new animal model for hepatitis C 2What happens when we sleep 2
... Designed specifically for high efficiency ... Low toxicity reagent proven to ... range of cell types. Results ... 95% of target gene expression. ...
... measurements in an easy-to-use benchtop package. ... spectrometer (ESI-oa-TOF) concentrates the performance of ... which fits on your bench. The ... 10,000 FWHM and mass accuracy of ...
... The lower cost and reduced ... system make reference standard DNA analysis ... be used with any of SEQUENOM's ... High-Performance Genotyping (iPLEXTM Gold) , Gene ...
... jetSI-ENDO-FluoR is a tetramethylrhodamine-conjugated jetSI-ENDO ... at 580 nm), the powerful ... are used to determine the ... intracellular delivery and trafficking of ...
Biology Products: